EUVIMEDEUVIMED entdecken
Crossref

Sequential Janus Kinase Inhibitor Switching in Ulcerative Colitis Patients Maintaining Remission: A Multicenter Experience

Genta Uchida, Tsunaki Sawada, Masanao Nakamura, Takeshi Yamamura, Keiko Maeda, Eri Ishikawa, Kentaro Murate, Tomoyuki Tsuzuki, Hiroki Kawashima

Digestion · 21.04.2026 · 1-6

DOI: 10.1159/000552136 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Digestion, online erschienen am 21.04.2026. Verfasst von Genta Uchida und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Toyota Kosei Hospital, Toyota, Japan. Die Arbeit nennt 13 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Given the safety concerns associated with the long-term use of Janus kinase (JAK) inhibitors, establishing effective “exit strategies” is crucial for patients with ulcerative colitis (UC). This study investigated the efficacy and safety of switching from tofacitinib (TOF) or upadacitinib (UPA) to the JAK1-selective filgotinib (FIL) in patients maintaining remission.

Methods

We conducted a retrospective, multicenter study involving 13 UC patients who achieved clinical remission with TOF or UPA and subsequently switched to FIL. The primary endpoint was the cumulative non-relapse rate.

Results

During a median follow-up of 679 days, symptomatic relapse occurred in 53.8% (7/13) of patients. The 1-year cumulative non-relapse rate was 71.4% for the TOF-switch group and 31.3% for the UPA-switch group. However, many relapses were successfully managed through temporary treatment adjustments, including FIL dose escalation or topical therapy. No serious adverse events were recorded.

Conclusion

Sequential switching to FIL may represent a practical intermediate maintenance strategy before complete drug withdrawal, balancing disease control with potential safety benefits.

Schlagwörter

Stichwörter der Autor:innen

De-escalationFilgotinibJanus kinase inhibitorSequential therapyUlcerative colitis

Autor:innen und Institutionen

  • Department of Gastroenterology and Hepatology, Toyota Kosei Hospital, Toyota, Japan.
  • Department of Endoscopy, Nagoya University Hospital, Nagoya, Japan, sawada.tsunaki.d5@f.mail.nagoya-u.ac.jp).
  • Department of Gastroenterology, Aichi Medical University School of Medicine, Nagakute, Japan.
  • Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Zitieren

APA

Uchida, G., Sawada, T., Nakamura, M., Yamamura, T., Maeda, K., Ishikawa, E., Murate, K., Tsuzuki, T., & Kawashima, H. (2026). Sequential Janus Kinase Inhibitor Switching in Ulcerative Colitis Patients Maintaining Remission: A Multicenter Experience. Digestion, 1-6. https://doi.org/10.1159/000552136

Vancouver

Uchida G, Sawada T, Nakamura M, Yamamura T, Maeda K, Ishikawa E, et al. Sequential Janus Kinase Inhibitor Switching in Ulcerative Colitis Patients Maintaining Remission: A Multicenter Experience. Digestion. 2026:1-6. doi:10.1159/000552136

BibTeX
@article{Uchida2026,
  author = {Uchida, Genta and Sawada, Tsunaki and Nakamura, Masanao and Yamamura, Takeshi and Maeda, Keiko and Ishikawa, Eri and Murate, Kentaro and Tsuzuki, Tomoyuki and Kawashima, Hiroki},
  title = {Sequential Janus Kinase Inhibitor Switching in Ulcerative Colitis Patients Maintaining Remission: A Multicenter Experience},
  journal = {Digestion},
  year = {2026},
  pages = {1--6},
  doi = {10.1159/000552136}
}
Kostenlos starten →